Nintedanib Dose Reductions in IPF May Do No Harm : vimarsana

Patients with idiopathic pulmonary fibrosis who required dose reductions had similar all-cause mortality and death rates vs patients on the full dose.

Related Keywords

Hawaii , United States , Mayo Clinic In Rochester , Minnesota , Honolulu , Misbah Baqir , Lakes Foundation , American College Of Chest Physicians , Andrew Limper , Mayo Clinic , American College , Chest Physicians , Optumlabs Data Warehouse , Medscape Medical News , Three Lakes , Nintedanib Dosing , Clinical Outcomes , Real World , Presented October , Idiopathic Pulmonary Fibrosis , Lung Fibrosis , Pulmonary Fibrosis , Ibrosis Pulmonary , Adverse Events Pharmacology , Chronic Disease , Chronic Illness , Interstitial Lung Disease , Adverse Effects , Side Effects , Lung , Quality Of Life , Pol , Ealth Related Quality Of Life , Rqol , Systemic Sclerosis , Diffuse Scleroderma , Diarrhea , Patient Safety , Scleroderma , Crest Syndrome , Toxico ,